Every 8-K that INTENSITY THERAPEUTICS INC (INTS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow INTS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INTS filings page.
Intensity Therapeutics reported second-quarter 2026 results and highlighted progress in its late-stage oncology pipeline. The company is resuming enrollment at select U.S. sites in the Phase 3 INVINCIBLE-3 soft tissue sarcoma trial under an FDA-reviewed amended protocol, after a prior pause tied to funding constraints. In the Phase 2 INVINCIBLE-4 presurgical triple negative breast cancer study, preliminary data from 14 patients showed a 71% pathological complete response rate with INT230-6 plus standard-of-care (Cohort A) versus 42% with standard-of-care alone (Cohort B), and a 44% reduction in grade 3 adverse events in Cohort A.
For the quarter ended June 30, 2026, research and development expenses were $1.8 million and general and administrative expenses were $1.3 million, leading to a net loss of $3.0 million or $1.11 per share. For the first six months of 2026, net loss was $5.4 million. Cash and cash equivalents totaled $9.5 million as of June 30, 2026. The company established a $60 million at-the-market facility and raised net proceeds of $1.6 million in the second quarter, with an additional $1.3 million raised after quarter-end.
Intensity Therapeutics, Inc. reported the results of its 2026 annual stockholder meeting held via live webcast. A total of 1,079,494 shares of common stock, representing approximately 40.74% of shares entitled to vote, were present, establishing a quorum.
Stockholders elected Dr. Emer Leahy and Lewis H. Bender as Class III directors to serve until the 2029 annual meeting. They also ratified EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Stockholders approved an amendment to the 2021 Stock Incentive Plan to add 150,000 shares and an amendment to the 2024 Employee Stock Purchase Plan to add 25,000 shares for issuance. They further approved the potential adjournment of the meeting, if necessary, to solicit additional proxies on the listed proposals.
Intensity Therapeutics, Inc. reported first quarter 2026 results and provided a clinical update. Net loss narrowed to $2.4 million for the three months ended March 31, 2026, compared with $3.3 million a year earlier, as lower research and development spending offset bonus accruals.
Research and development expenses were $1.2 million versus $2.2 million in 2025, while general and administrative expenses were $1.3 million versus $1.2 million. Cash and cash equivalents totaled $10.2 million as of March 31, 2026. Early data from the Phase 2 INVINCIBLE-4 TNBC study showed higher pathological complete response rates and fewer severe adverse events in patients receiving INT230-6 before standard of care, and regulators approved resumption of enrollment. The company also plans to restart limited U.S. enrollment in its Phase 3 INVINCIBLE-3 soft tissue sarcoma study by the third quarter of 2026.
Intensity Therapeutics reported a narrower 2025 net loss of $11.6M, improved from $16.3M in 2024, as research and development and general and administrative expenses declined. The company raised over $20M during 2025, ending the year with $11.9M in cash and cash equivalents and a stated cash runway into the second quarter of 2027.
Clinically, preliminary data from the INVINCIBLE-4 breast cancer study showed a pathological complete response rate of 71.4% (5/7) for patients receiving INT230-6 plus standard of care versus 33% (2/6) for standard of care alone, with fewer severe adverse events. A Lancet eBioMedicine publication from the IT-01 study reported a 75% disease control rate and median overall survival of 11.9 months in heavily pretreated metastatic patients. The INVINCIBLE-3 phase 3 sarcoma trial remains paused for new enrollment due to prior funding constraints, though the company continues treating enrolled patients and plans to restart once additional funding is obtained.
Intensity Therapeutics, Inc. expanded the capacity of its existing at-the-market stock offering program to $60.0 million through a new prospectus supplement. This program lets the company sell common shares from time to time through H.C. Wainwright & Co. LLC.
The company is under no obligation to issue any shares and will decide whether to use the facility based on market conditions and strategic priorities. Management describes the expanded ATM as a way to enhance financial flexibility, giving the company an efficient mechanism to access equity capital if and when it chooses.
Intensity Therapeutics, Inc. reported that it has regained compliance with Nasdaq’s minimum bid price listing requirement. Nasdaq confirmed that the company’s common stock maintained a closing bid price of at least $1.00 per share for 10 consecutive business days from February 19, 2026 through March 4, 2026, and the matter is now closed.
The company had previously received Nasdaq deficiency notices in June and December 2025 after its share price stayed below $1.00, and was given until June 1, 2026 to regain compliance. Intensity also issued a press release describing its late-stage clinical focus and lead intratumoral cancer therapy candidate INT230-6, which is being evaluated in multiple Phase 2 and Phase 3 studies.
Intensity Therapeutics, Inc. furnished an update to its investor materials, providing an unaudited Financial Highlights Slide through December 31, 2025. The slide, dated March 4, 2026, is available on the company’s investor relations website and is also attached as an exhibit.
The figures in this slide are preliminary and subject to completion of financial closing procedures and management review, so they may differ materially from the final results reported in the company’s year-end financial statements.
Intensity Therapeutics, Inc. approved and implemented a 1-for-25 reverse stock split of its common stock to take legal effect at 4:01 p.m. Eastern Time on February 18, 2026. The shares are expected to begin trading on a split-adjusted basis on The Nasdaq Capital Market on February 19, 2026 under the existing ticker INTS but with a new CUSIP 45828J 202.
Every 25 issued and outstanding shares will be converted into 1 share, with no change to the total number of authorized shares. Fractional shares will not be issued; instead, affected stockholders will receive cash based on the February 18, 2026 closing price. The company estimates that outstanding shares will decrease from approximately 63,346,579 as of February 12, 2026 to approximately 2,533,863, with proportional adjustments to stock options, warrants, convertible securities and equity plan share counts.
Intensity Therapeutics (INTS) furnished an Item 2.02 8‑K announcing its financial results for the three and nine months ended September 30, 2025. The company released the details via a press release attached as Exhibit 99.1. The information is being furnished and shall not be deemed “filed” under the Exchange Act, nor incorporated by reference into Securities Act or Exchange Act filings except as expressly set forth by specific reference.
The 8‑K reiterates standard forward‑looking statement cautions and points readers to the company’s Form 10‑K and recent Form 10‑Qs for risk factors and additional context.
Intensity Therapeutics (INTS) entered a securities purchase agreement for a registered direct offering of 5,000,000 shares of common stock at $0.80 per share, for $4.0 million in aggregate gross proceeds. The shares are being offered off the company’s Form S-3 (File No. 333-280681), declared effective on July 11, 2024.
The transaction is expected to close on or about November 3, 2025, subject to customary closing conditions. The company engaged A.G.P./Alliance Global Partners as placement agent and agreed to pay a cash fee equal to 7.0% of gross proceeds and reimburse documented out-of-pocket expenses, including legal fees up to $50,000. The purchase agreement includes customary terms and a 30-day restriction on issuing or selling additional common stock or common stock equivalents following closing.
On October 31, 2025, the company announced pricing via a press release incorporated as an exhibit.
Intensity Therapeutics (INTS) reported voting results from its October 22, 2025 special meeting. Stockholders approved an amendment allowing a reverse stock split of common stock at a ratio between 1-for-5 and 1-for-30. The board may set the exact ratio in its sole discretion, may choose not to effect the split, and the action will not reduce the authorized number of common shares.
A quorum was present with 22,869,562 shares represented, or 46.61% of shares entitled to vote. Proposal 1 (reverse split authorization) passed with 18,333,570 For, 4,508,502 Against, and 27,490 Abstain. Proposal 2 (potential adjournment) was also approved with 18,869,741 For, 3,893,779 Against, and 106,042 Abstain.
Intensity Therapeutics reported an update on its INVINCIBLE-4 study involving its drug candidate INT230-6. The company observed a pathological complete response in the first patient evaluated in Cohort A, where patients receive two doses of INT230-6 eight days apart followed by standard immunochemotherapy. The company stated that, to date, the safety profile in Cohort A looks favorable, although some patients experienced localized skin irritation near the tumor site. Because of these local skin effects, new patient enrollment in Cohort A has been paused while the team evaluates the collected data and implements any necessary protocol adjustments before reopening enrollment.
Intensity Therapeutics amended its bylaws to change the quorum for stockholder meetings from a majority to at least one-third of the voting power, whether present in person, by remote communication, or represented by proxy. The Board adopted the amendment effective August 12, 2025 and filed the full text as Exhibit 3.1. Separately, Nasdaq notified the company that it was not in compliance with the $2,500,000 stockholders' equity requirement, the company raised approximately $6.6 million in July through an at-the-market offering, and its quarterly report for the period ended June 30, 2025 states it believes it meets the equity requirement. Nasdaq has determined the company currently complies but warned that failure to evidence compliance at the next periodic report could lead to delisting procedures.
On 7 Aug 2025, Intensity Therapeutics, Inc. (Nasdaq: INTS) filed a Form 8-K to report the release of its financial results for the three and six months ended 30 Jun 2025. The filing itself does not contain any revenue, EPS or cash-flow figures; instead, management refers investors to the detailed data contained in the accompanying press release (Exhibit 99.1). No other material corporate actions, transactions, or leadership changes were disclosed. Standard forward-looking-statement language and exhibit listings (including an Inline XBRL cover page) are provided, and the company continues to qualify as an emerging growth company.